Information Provided By:
Fly News Breaks for February 10, 2016
REGN
Feb 10, 2016 | 07:34 EDT
UBS said the bull case for Regeneron weakened following its Q4 earnings miss, citing lower Eylea growth projected for this year. The firm believes that despite the lower results, its earnings ramp is still significant and ample pipeline catalysts remain. UBS reiterated its Buy rating but lowered its price target to $575 from $645 on Regeneron shares.